Feed JANX
JA

Janux Therapeutics, Inc.

JANX · NASDAQ

$16.59 -1.37% (-$0.23)
1M -10.81%
Market Cap $1.01B
P/E Ratio -
Div. Yield -
ROE 10.79%

Bulios Fair Price

$10.75

35.2% downside

Trenutna cena

$16.59

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica JANX trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
50 /100
Fair
P/S 31.74x
P/B 1.09x
P/E N/A
Growth
58 /100
Stable
Rev. growth 5.11%
Book val. growth 43.95%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 68.91%
FCF margin 171.06%
Net margin 321.81%
Quality
0 /100
Poor
ROIC 15.11%
Asset turnover 0.03x
ROE 10.79%
Debt
100 /100
Low
Debt/Equity 0.02x
Current ratio 16.35x
Int. coverage N/A
Stability
36 /100
Moderate
Beta 2.52x
Profitable years 0
Rev. volatility 21.27%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o JANX
Online

O podjetju

Janux Therapeutics is a biotechnology company focused on developing advanced therapeutic methods for cancer immunotherapy. The company specializes in utilizing its platform, which combines antibody technology with targeted therapeutic agents, to enhance the body's natural defense against cancer cells. Janux is developing various products, including bioconjugates, that aim to specifically target and destroy cancer cells while minimizing side effects on healthy tissues.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

David Alan Campbell

Employees

113

Headquarters

San Diego

Prihajajoči dogodki

05 NOV.

Earnings

Upcoming earnings report

45d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.